Obesity/Overweight – Unmet Need – Detailed, Expanded Analysis (US/EU)
Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and adverse cardiovascular (CV) health. Since 2012, several novel branded drugs have entered the market with varying degrees of commercial success. Approved agents include Novo Nordisk’s Wegovy (semaglutide) and Saxenda (liraglutide), Vivus’s Qsymia (phentermine / topiramate), and Nalpropion Pharmaceuticals’ Contrave (naltrexone / bupropion). In this report, endocrinologists compare current antiobesity drugs and discuss the attributes that the next generation of drugs should have to serve this medically important population and to succeed commercially in a potentially lucrative market.
QUESTIONS ANSWERED
- How do endocrinologists rate current antiobesity drugs, such as Novo Nordisk’s Wegovy and Saxenda?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- What trade-offs across different clinical attributes and prices are needed from new obesity drugs to be preferred by endocrinologists?
- How can less-frequent dosing, route of administration, cardiovascular and renal benefit, and efficacy influence physician preference? Discover the answers with Clarivate’s fully customizable Target Product Profile (TPP) simulator.
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European endocrinologists fielded in March 2023
Key companies: Novo Nordisk, Vivus, Currax Pharmaceuticals, Orexigen Therapeutics
Key drugs: Wegovy, Saxenda, Qsymia, Contrave/Mysimba, Xenical, phentermine
Table of contents
- Obesity/Overweight - Unmet Need - Detailed, Expanded Analysis (US/EU)
- Executive summary
- Unmet Need - Obesity - Executive Summary - June 2023
- Introduction
- Overview
- Methodology
- Rationale for treatment drivers and goals selection
- Rationale for drug selection
- Products for obesity and rationale for drug selection
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed endocrinologists' prescribing decisions in obesity
- Importance of efficacy attributes to prescribing decisions in obesity: United States
- Importance of efficacy attributes to prescribing decisions in obesity: Europe
- Importance of safety and tolerability attributes to prescribing decisions in obesity: United States
- Importance of safety and tolerability attributes to prescribing decisions in obesity: Europe
- Importance of convenience of administration attributes to prescribing decisions in obesity: United States
- Importance of convenience of administration attributes to prescribing decisions in obesity: Europe
- Importance of nonclinical factors to prescribing decisions in obesity: United States
- Importance of nonclinical factors to prescribing decisions in obesity: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in obesity: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in obesity: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for obesity: United States
- Overall performance of key therapies for obesity: Europe
- Mean overall performance of key therapies for obesity: United States and Europe
- Relative performance of key therapies for obesity across select efficacy attributes: United States
- Relative performance of key therapies for obesity across select efficacy attributes: Europe
- Relative performance of key therapies for obesity across select safety and tolerability attributes: United States
- Relative performance of key therapies for obesity across select safety and tolerability attributes: Europe
- Relative performance of key therapies for obesity across select convenience of administration attributes: United States
- Relative performance of key therapies for obesity across select convenience of administration attributes: Europe
- Relative performance of key therapies for obesity across select nonclinical attributes: United States
- Relative performance of key therapies for obesity across select nonclinical attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in obesity
- Surveyed endocrinologistsu2019 satisfaction with the performance of key therapies for obesity on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed endocrinologistsu2019 satisfaction with the performance of key therapies for obesity on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed endocrinologists' ascribed level of unmet need across key efficacy attributes in obesity: United States
- Surveyed endocrinologists' ascribed level of unmet need across key efficacy attributes in obesity: Europe
- Surveyed endocrinologists' ascribed level of unmet need across key safety and tolerability attributes in obesity: United States
- Surveyed endocrinologists' ascribed level of unmet need across key safety and tolerability attributes in obesity: Europe
- Surveyed endocrinologists' ascribed level of unmet need across key convenience of administration attributes in obesity: United States
- Surveyed endocrinologists' ascribed level of unmet need across key convenience of administration attributes in obesity: Europe
- Surveyed endocrinologists' ascribed level of unmet need across key nonclinical factors in obesity: United States
- Surveyed endocrinologists' ascribed level of unmet need across key nonclinical factors in obesity: Europe
- Key findings: unmet need in obesity and related indications
- Surveyed endocrinologists' ascribed level of unmet need in obesity and related indications: United States
- Surveyed endocrinologists' ascribed level of unmet need in obesity and related indications: Europe
- Opportunity analysis
- Areas of opportunity in the obesity market and emerging therapy insights
- Opportunity: antiobesity agents offering sustained body-weight loss
- Opportunity: antiobesity agents effective in reducing cardiovascular adverse events
- Opportunity: antiobesity agents effective in reducing body fat and preventing adiposopathy
- Areas of opportunity in the obesity market and emerging therapy insights
- Target product profiles
- Assessing drug development opportunities
- Target product profile methodology
- Attributes and attribute levels
- Attribute importance and part-worth utilities
- Obesity target product profile: attribute importance
- Mean body-weight loss after one year
- Mean reduction in body fat after one year
- Mean reduction in HbA1c after one year (in diabetics)
- Mean reduction in cardiovascular adverse event rates
- Risk of neuropsychiatric adverse events
- Dosing burden
- Price per day
- Conjoint analysis-based simulation of a market scenario
- Obesity market simulation: share of preference of target product profiles included in the market scenario
- Obesity market simulation: likelihood to prescribe of target product profiles included in the market scenario
- Obesity market simulation: target product profiles included in the market scenario
- Appendix
- Key abbreviations
- Bibliography
- Executive summary
Carles Recasens-Alvarez, M.Sc., Ph.D., Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematology. Prior to joining Clarivate, Dr. Recasens-Alvarez was a postdoctoral researcher in the laboratory of Jean-Paul Vincent at the Francis Crick Institute (London), where he investigated the role of protein misfolding and cellular stress in the etiology of ribosomopathies and lead-authored a manuscript. For his doctoral research, he studied the role of cell cycle and apoptosis in development in the laboratory of Professor Marco Milan at the Institute for Research in Biomedicine (Barcelona). He holds a Ph.D. and an M.Sc. in genetics, both from the University of Barcelona, and a B.Sc. in biology from the Autonomous University of Barcelona.
Tej Pal, M.Pharm., is a senior healthcare research & data analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Diseases team at Clarivate. He has authored several reports focusing on metabolic and renal indications. Previously, he was an analyst at IQVIA and at Smart Analyst Inc., where he worked closely with top pharmaceutical companies on commercial and technical ad-hoc requests. During his tenure there, he delivered competitive landscape and market insight projects on various oncology indications. He holds a master’s degree in pharmacy with a specialization in pharmaceutical chemistry from the Delhi Institute of Pharmaceutical Sciences and Research in New Delhi, India.